Re:Cognition Health launches first dedicated Alzheimer's disease-modifying treatment clinic in Ireland

Re:Cognition Health, the UK's largest independent provider of Alzheimer's disease-modifying treatments, announces the opening of its first Irish clinic in Dublin, marking a major milestone in dementia care for Ireland.

Located at Tallaght Cross East, Dublin, the new clinic will become the first dedicated independent memory center in Ireland offering access to Alzheimer's disease-targeting therapies, including Leqembi® (lecanemab) and Kisunla® (donanemab) for eligible patients with early Alzheimer's disease.

The launch follows the approval of both medicines in Ireland, representing one of the most significant advances in Alzheimer's treatments. Unlike traditional dementia medications, which manage just the symptoms of Alzheimer’s disease, Leqembi and Kisunla are anti-amyloid monoclonal antibodies that target and remove the toxic amyloid protein s in the brain, the hallmark of Alzheimer's disease. Clinical trials have shown these treatments can slow disease progression in individuals with an accurate diagnosis of Alzheimer's, during the early stages of this condition.

Until now, many Irish patients seeking access to these breakthrough therapies have travelled to one of Re:Cognition Health’s Clinics in the UK for specialist assessment, diagnostic investigations and ongoing treatment. Re:Cognition Health has experienced substantial demand from patients and families across Ireland, highlighting both the unmet need for specialist memory services and the desire for treatment closer to home.